Cubist Systematic Strategies LLC Acquires New Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Cubist Systematic Strategies LLC bought a new position in Immunocore Holdings plc (NASDAQ:IMCR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 106,600 shares of the company’s stock, valued at approximately $3,145,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of Immunocore in the fourth quarter worth $5,697,000. The Manufacturers Life Insurance Company grew its stake in shares of Immunocore by 6.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 114,151 shares of the company’s stock valued at $3,367,000 after purchasing an additional 6,760 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Immunocore by 3.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company’s stock worth $197,657,000 after purchasing an additional 200,373 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Immunocore by 1.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company’s stock worth $64,533,000 after buying an additional 29,832 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Trading Down 4.7 %

Shares of IMCR opened at $28.40 on Friday. The firm has a market cap of $1.42 billion, a P/E ratio of -29.89 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $59.82. The company has a 50 day simple moving average of $28.81 and a two-hundred day simple moving average of $30.15.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same period in the previous year, the firm posted ($0.49) EPS. Immunocore’s revenue for the quarter was up 33.6% compared to the same quarter last year. On average, equities analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on IMCR. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. Oppenheimer boosted their price target on Immunocore from $85.00 to $86.00 and gave the company an “outperform” rating in a report on Thursday. Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research note on Monday, April 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average price target of $58.13.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.40% of the stock is owned by company insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.